Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach

BGMA Chair Diane DiGangi Trench Explains Why A Fresh Relationship With Industry Is Needed

Executive Summary

With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.

You may also be interested in...



UK Body Urges Action On Licensing Delays As MHRA Unveils Guidance For Established Products

UK MHRA guidance outlining process changes aimed at shortening timeframes for assessing established medicines has been welcomed by the BGMA, which has emphasized the need to clear the regulator’s current approvals backlog that the association says is exacerbating shortages.

New Critical Medicines Alliance Says Join Us In Tackling Critical Medicines Shortages

Diversification of global supply chains, drug stockpiling, and boosting Europe's capacity to produce and innovate in the manufacturing of critical medicines and their ingredients are among the topics to be addressed by the European Commission’s forthcoming Critical Medicines Alliance.

BGMA Denied In Bid To Negotiate Over VPAS Rebate Scheme

UK generics and biosimilars industry association the BGMA has been denied in its bid to overturn a government decision to exclude it from formal negotiations over the VPAS rebate scheme.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel